Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated With Trastuzumab and Pertuzumab
In HER2-positive breast cancer, CTRCD occurred more frequently in patients using anthracycline followed by trastuzumab and pertuzumab simultaneously. Systolic dysfunction was reversible in all patients, and normalization of cardiac function took approximately 4 months from CTRCD onset.
Authors
- Yuko Takano (ORCID: https://orcid.org/0000-0002-3753-7683)
- Ryota Morimoto (ORCID: https://orcid.org/0000-0003-0931-3188)
- Yuichi Ando
- Yoshiyuki Bando (ORCID: https://orcid.org/0000-0003-4166-6784)
- Reina Ozaki
- Hiroaki Hiraiwa (ORCID: https://orcid.org/0000-0002-1606-7037)
- Tomoya Shimokata
- Toyone Kikumori
- Toru Kondo (ORCID: https://orcid.org/0000-0001-6853-7574)
- Masahiko Ando (ORCID: https://orcid.org/0000-0003-2891-5424)
- Yachiyo Kuwatsuka (ORCID: https://orcid.org/0000-0001-6092-3948)
- S. Kazama (ORCID: https://orcid.org/0000-0002-6976-3693)
- Toyoaki Murohara
Institutions
- Mie University (JP)
- Nagoya University Hospital (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Circulation Reports
- Published
- 2025-07-18
- DOI
- https://doi.org/10.1253/circrep.cr-25-0036
- Citations
- 3
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 4.16
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Taiho Pharmaceutical
- Kowa Company
- BeiGene
- Boehringer Ingelheim Japan
- Incyte
- Abiomed
- Daiichi-Sankyo
- Astellas Pharma
- Ono Pharmaceutical
- Novartis Pharma
- Chugai Pharmaceutical
- Japan Society for the Promotion of Science
- Daiichi Sankyo Europe